3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Ovarian Neoplasms
17
Fallopian Tube Neoplasms
17
Carcinoma, Non-Small-Cell Lung
8
Glioblastoma
7
Carcinoma, Renal Cell
7
Lung Neoplasms
6
Colorectal Neoplasms
6
Brenner Tumor
6
Squamous Cell Carcinoma of Head and Neck
5
Melanoma
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Prostatic Neoplasms
4
Gliosarcoma
4
Breast Neoplasms
4
Brain Neoplasms
4
Recurrent Squamous Cell Lung Carcinoma
3
Oligodendroglioma
3
Neoplasm Metastasis
3
Lymphoma, Large B-Cell, Diffuse
3
Uveal Melanoma
2
Urinary Bladder Neoplasms
2
Spinal Cord Neoplasms
2
Medulloblastoma
2
Glioma
2
Endometrial Adenocarcinoma
2
Colonic Neoplasms
2
Carcinoma
2
Astrocytoma
2
Adenocarcinoma of Lung
2
Interventions
Trastuzumab
3
Sugammadex
2
Neostigmine
2
Cisplatin
2
valrubicin
1
tucatinib
1
pembrolizumab
1
niraparib
1
enfortumab vedotin
1
avelumab
1
atezolizumab
1
Surveys and Questionnaires
1
Sunitinib
1
Standard of Care
1
Rocuronium
1
Pemetrexed
1
Paclitaxel
1
Nephroureterectomy
1
Neoadjuvant Therapy
1
Mitomycin
1
Lymph Node Excision
1
Glycopyrrolate
1
Gemcitabine
1
GSK-3326595
1
Fulvestrant
1
Docetaxel
1
Cetuximab
1
Afatinib
1
Administration, Intravesical
1
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Urologic Neoplasms
×
Immunoglobulin G
×
Clear all
No trials found.